ELEVAI LABS, a biotech company leveraging human stem cell exosomes to create topical skin care products, has signed a non-exclusive global distributor and trademark license agreement with DermapenWorld, maker of the Dermapen microneedling device.
Under the agreement, DermapenWorld will purchase specified minimum quantities of ELEVAI Exosomes, which will become a key ingredient within its Dp Dermaceuticals MG-EXO-SKIN, as well as Enfinity daily serum, which will be packaged in DermapenWorld’s Dp Dermaceuticals packaging.
“ELEVAI is proud to partner with DermapenWorld, a global leader in microneedling and aesthetic products. By combining our companies’ strengths, we can now offer skin care professionals the latest in microneedling and stem cell exosome technology — products designed to work together synergistically to provide unparalleled results with minimal downtime,” said Tim Sayed, MD, plastic surgeon and ELEVAI co-founder and chief medical officer.
